Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions

Ebbing P. de Jong, Hongwei Xie, Getiria Onsongo, Matthew D. Stone, Xiao Bing Chen, Joel A. Kooren, Eric W. Refsland, Robert J. Griffin, Frank G. Ondrey, Baolin Wu, Chap T. Le, Nelson L. Rhodus, John V. Carlis, Timothy J. Griffin

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


Background Oral cancer survival rates increase significantly when it is detected and treated early. Unfortunately, clinicians now lack tests which easily and reliably distinguish pre-malignant oral lesions from those already transitioned to malignancy. A test for proteins, ones found in non-invasively-collected whole saliva and whose abundances distinguish these lesion types, would meet this critical need. Methodology/Principal Findings To discover such proteins, in a first-of-its-kind study we used advanced mass spectrometry-based quantitative proteomics analysis of the pooled soluble fraction of whole saliva from four subjects with pre-malignant lesions and four with malignant lesions. We prioritized candidate biomarkers via bioinformatics and validated selected proteins by western blotting. Bioinformatic analysis of differentially abundant proteins and initial western blotting revealed increased abundance of myosin and actin in patients with malignant lesions. We validated those results by additional western blotting of individual whole saliva samples from twelve other subjects with pre-malignant oral lesions and twelve with malignant oral lesions. Sensitivity/specificity values for distinguishing between different lesion types were 100%/75% (p = 0.002) for actin, and 67%/83% (p<0.00001) for myosin in soluble saliva. Exfoliated epithelial cells from subjects' saliva also showed increased myosin and actin abundance in those with malignant lesions, linking our observations in soluble saliva to abundance differences between pre-malignant and malignant cells. Conclusions/Significance Salivary actin and myosin abundances distinguish oral lesion types with sensitivity and specificity rivaling other non-invasive oral cancer tests. Our findings provide a promising starting point for the development of non-invasive and inexpensive salivary tests to reliably detect oral cancer early.

Original languageEnglish (US)
Article numbere11148
JournalPloS one
Issue number6
StatePublished - 2010

Bibliographical note

Funding Information:
This work was funded in part by an unrestricted research award to the corresponding author from Eli Lilly and Co. The corresponding author has no other relationship with Eli Lilly and Co. other than this research award. The company had no role in study design, collection, analysis and interpretation of data, writing of the paper, or decision to submit for publication. Furthermore, this relationship does not impede the authors' ability to adhere to all the PLoS ONE policies on sharing data and materials.


Dive into the research topics of 'Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions'. Together they form a unique fingerprint.

Cite this